Kimberly S. Andrews
American Cancer Society
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kimberly S. Andrews.
Gastroenterology | 2008
Bernard Levin; David A. Lieberman; Beth McFarland; Kimberly S. Andrews; Durado Brooks; John H. Bond; Chiranjeev Dash; Francis M. Giardiello; Seth N. Glick; David A. Johnson; C. Daniel Johnson; Theodore R. Levin; Perry J. Pickhardt; Douglas K. Rex; Robert A. Smith; Alan G. Thorson; Sidney J. Winawer
In the United States, colorectal cancer (CRC) is the third most common cancer diagnosed among men and women and the second leading cause of death from cancer. CRC largely can be prevented by the detection and removal of adenomatous polyps, and survival is significantly better when CRC is diagnosed while still localized. In 2006 to 2007, the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology came together to develop consensus guidelines for the detection of adenomatous polyps and CRC in asymptomatic average-risk adults. In this update of each organizations guidelines, screening tests are grouped into those that primarily detect cancer early and those that can detect cancer early and also can detect adenomatous polyps, thus providing a greater potential for prevention through polypectomy. When possible, clinicians should make patients aware of the full range of screening options, but at a minimum they should be prepared to offer patients a choice between a screening test that primarily is effective at early cancer detection and a screening test that is effective at both early cancer detection and cancer prevention through the detection and removal of polyps. It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening.
CA: A Cancer Journal for Clinicians | 2007
Carla Boetes; Wylie Burke; Steven E. Harms; Martin O. Leach; Constance D. Lehman; Elizabeth A. Morris; Etta D. Pisano; Mitchell D. Schnall; Stephen F. Sener; Robert A. Smith; Ellen Warner; Martin J. Yaffe; Kimberly S. Andrews; Christy A. Russell
New evidence on breast Magnetic Resonance Imaging (MRI) screening has become available since the American Cancer Society (ACS) last issued guidelines for the early detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed new recommendations for women at different defined levels of risk. Screening MRI is recommended for women with an approximately 20–25% or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin disease. There are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mammography. Diagnostic uses of MRI were not considered to be within the scope of this review.
CA: A Cancer Journal for Clinicians | 2009
Robert A. Smith; Kimberly S. Andrews; Durado Brooks; Carol DeSantis; Stacey A. Fedewa; Joannie Lortet-Tieulent; Deana Manassaram-Baptiste; Otis W. Brawley; Richard Wender
Answer questions and earn CME/CNE
CA: A Cancer Journal for Clinicians | 2008
Bernard Levin; David A. Lieberman; Beth McFarland; Robert A. Smith; Durado Brooks; Kimberly S. Andrews; Chiranjeev Dash; Francis M. Giardiello; Seth N. Glick; Theodore R. Levin; Perry J. Pickhardt; Douglas K. Rex; Alan G. Thorson; Sidney J. Winawer
In the United States, colorectal cancer (CRC) is the third most common cancer diagnosed among men and women and the second leading cause of death from cancer. CRC largely can be prevented by the detection and removal of adenomatous polyps, and survival is significantly better when CRC is diagnosed while still localized. In 2006 to 2007, the American Cancer Society, the US Multi Society Task Force on Colorectal Cancer, and the American College of Radiology came together to develop consensus guidelines for the detection of adenomatous polyps and CRC in asymptomatic average‐risk adults. In this update of each organizations guidelines, screening tests are grouped into those that primarily detect cancer early and those that can detect cancer early and also can detect adenomatous polyps, thus providing a greater potential for prevention through polypectomy. When possible, clinicians should make patients aware of the full range of screening options, but at a minimum they should be prepared to offer patients a choice between a screening test that is effective at both early cancer detection and cancer prevention through the detection and removal of polyps and a screening test that primarily is effective at early cancer detection. It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening.
CA: A Cancer Journal for Clinicians | 1997
Andrew M.D. Wolf; Richard Wender; Ruth Etzioni; Ian M. Thompson; Anthony V. D'Amico; Robert J. Volk; Durado Brooks; Chiranjeev Dash; Idris Guessous; Kimberly S. Andrews; Carol DeSantis; Robert A. Smith
In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection. A series of systematic evidence reviews was conducted focusing on evidence related to the early detection of prostate cancer, test performance, harms of therapy for localized prostate cancer, and shared and informed decision making in prostate cancer screening. The results of the systematic reviews were evaluated by the ACS Prostate Cancer Advisory Committee, and deliberations about the evidence occurred at committee meetings and during conference calls. On the basis of the evidence and a consensus process, the Prostate Cancer Advisory Committee developed the guideline, and a writing committee drafted a guideline document that was circulated to the entire committee for review and revision. The document was then circulated to peer reviewers for feedback, and finally to the ACS Mission Outcomes Committee and the ACS Board of Directors for approval. The ACS recommends that asymptomatic men who have at least a 10‐year life expectancy have an opportunity to make an informed decision with their health care provider about screening for prostate cancer after they receive information about the uncertainties, risks, and potential benefits associated with prostate cancer screening. Prostate cancer screening should not occur without an informed decision‐making process. Men at average risk should receive this information beginning at age 50 years. Men in higher risk groups should receive this information before age 50 years. Men should either receive this information directly from their health care providers or be referred to reliable and culturally appropriate sources. Patient decision aids are helpful in preparing men to make a decision whether to be tested. CA Cancer J Clin 2010;60:70–98.
CA: A Cancer Journal for Clinicians | 2012
Lawrence H. Kushi; Colleen Doyle; Marji McCullough; Cheryl L. Rock; Wendy Demark-Wahnefried; Elisa V. Bandera; Susan M. Gapstur; Alpa V. Patel; Kimberly S. Andrews; Ted Gansler
The American Cancer Society (ACS) publishes Nutrition and Physical Activity Guidelines to serve as a foundation for its communication, policy, and community strategies and, ultimately, to affect dietary and physical activity patterns among Americans. These Guidelines, published approximately every 5 years, are developed by a national panel of experts in cancer research, prevention, epidemiology, public health, and policy, and they reflect the most current scientific evidence related to dietary and activity patterns and cancer risk. The ACS Guidelines focus on recommendations for individual choices regarding diet and physical activity patterns, but those choices occur within a community context that either facilitates or creates barriers to healthy behaviors. Therefore, this committee presents recommendations for community action to accompany the 4 recommendations for individual choices to reduce cancer risk. These recommendations for community action recognize that a supportive social and physical environment is indispensable if individuals at all levels of society are to have genuine opportunities to choose healthy behaviors. The ACS Guidelines are consistent with guidelines from the American Heart Association and the American Diabetes Association for the prevention of coronary heart disease and diabetes, as well as for general health promotion, as defined by the 2010 Dietary Guidelines for Americans and the 2008 Physical Activity Guidelines for Americans. CA Cancer J Clin 2012.
CA: A Cancer Journal for Clinicians | 2007
Philip E. Castle; J. Thomas Cox; Diane D. Davey; Mark H. Einstein; Daron G. Ferris; Sue J. Goldie; Diane M. Harper; Walter Kinney; Anna-Barbara Moscicki; Kenneth L. Noller; Cosette M. Wheeler; Terri Ades; Kimberly S. Andrews; Mary Doroshenk; Kelly Green Kahn; Christy Schmidt; Omar Shafey; Robert A. Smith; Edward E. Partridge; Francisco Garcia
The American Cancer Society (ACS) has developed guidelines for the use of the prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical intraepithelial neoplasia and cervical cancer. These recommendations are based on a formal review of the available evidence. They address the use of prophylactic HPV vaccines, including who should be vaccinated and at what age, as well as a summary of policy and implementation issues. Implications for screening are also discussed.
Cancer | 2012
Kathryn H. Schmitz; Nicole L. Stout; Kimberly S. Andrews; Jill M. Binkley; Robert A. Smith
For most women in developed countries, breast cancer has become a survivable chronic disease. Improved survival has been achieved through steady improvements in early detection and therapy and has contributed to a growing population of breast cancer survivors. However, the natural emphasis on improved survival overshadows the reality that breast cancer survivors face a cascade of post-treatment challenges, principally surveillance for recurrence, but also near-term and longterm, treatment-related medical and psychological sequelae. One set of these sequelae includes physical impairments, such as fatigue, pain, postsurgical and persistent upper-quadrant issues, chemotherapy-induced peripheral neuropathy, lymphedema, cardiotoxic effects of chemotherapy and radiotherapy, weight gain, bone health challenges, and arthralgias. It is known that these impairments, many of which are amenable to rehabilitative and exercise interventions, lead to limitations and restrictions in the performance of common daily activities, including occupational and home activities. There are multiple barriers to addressing physical impairments secondary to treatment. One barrier is the fractured delivery of health care: Surgery, radiation, chemotherapy, and survivorship follow-up all may occur in separate health care systems. Other barriers are lack of established relationships between the oncology, general surgery, and plastic surgery professions and the rehabilitation and exercise professions, like what exists between the orthopedic surgery and rehabilitation professions. Furthermore, patients and their health care providers may have a sense that these sequelae are ‘‘expected’’ and normal and that they simply need to be tolerated. There is a general lack of understanding of the role that rehabilitation and exercise can have in ameliorating commonly experienced physical impairments after breast cancer. Even when all treatment occurs in the same health system, and even when that health system has electronic medical records, the referral
CA: A Cancer Journal for Clinicians | 2016
Kimberly S. Andrews; Deana Manassaram-Baptiste; Lacey Loomer; Kristina E. Lam; Marcie Fisher-Borne; Robert A. Smith; Elizabeth T. H. Fontham
Answer questions and earn CME/CNE
CA: A Cancer Journal for Clinicians | 2018
Andrew M.D. Wolf; Elizabeth T. H. Fontham; Timothy R. Church; Christopher R. Flowers; Carmen E. Guerra; Samuel J. LaMonte; Ruth Etzioni; Matthew T. McKenna; Kevin C. Oeffinger; Ya Chen Tina Shih; Louise C. Walter; Kimberly S. Andrews; Otis W. Brawley; Durado Brooks; Stacey A. Fedewa; Deana Manassaram-Baptiste; Rebecca L. Siegel; Richard Wender; Robert A. Smith
In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model‐recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high‐sensitivity stool‐based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average‐risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high‐sensitivity, guaiac‐based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250–281.